All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia

update of an illinois cancer center phase d pilot study

M. S. Tallman*, H. J. Miller, C. Anzig, A. Radmaker, Leo I Gordon, D. Hakimian, D. Variakojis, P. Stiff, S. French, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thirty-nine pa with non-M3 acute myetoid leukemia (AML) (median age 65) received ATRA ISO mg/mVday (d) onlly, low-oose cylostoe anbinoside (LD Ari-C) 10 mg/m1 twice diily lubcutaneouily d 1-14 lad gnnulocyte cotony-ttimuJatinj factor (G-CSF) (FUgrutim) 5 fif/kf/d nbcuuneouly d 1-28 of ach 2S-d cycle. Pu had either rdipud from prior CR (11 pu), were refractory to prior therapy (11 p), had failed reinduction (3 pu), were previously untreated but had evolved from in antecedent myelodyiplattic syndrome (MDS) (5 pis) or had de amo AML and were older thin 70 yean (9 pts). Pu achieving CR received the identical program but every 6 weeks {or 1 year. Fifteen pts are inevatuaMe for response [11 received < 30 days of treatment due to toxicity (10) or progressive disease (1); 2 died prior to the first follow-up marrow; 2 were ineligible]. Grade m and IV nonbematologic toxichies included headache, hyperfailirubinemia and stomatitis in 4 pts each; pulmonary in 3 (1 dyspnea, 2 pulmonary infiltrates); nausea/email in 3; neurologic in 3 (2 fatigue/weakness, 1 lightheadedness); hypotension in 3; and elevated transaminases, cardiac (trial fibrillation with transient CHF), rash, infection, musculoskeletal pain, the 'stiff man syndrome in 1 pt each. Three pB developed leukocytosis (peak WBC 65.6, 84.0, 123xlOVL). Six (25%) of the 24 évaluable pts achieved CR, 4 (17%) partial remission (PR), 4 (17) stable disease and 10 (42%) progressive disease. Among the 14 previously untreated pts, 4 (29%) achieved CR, and 1 (7%) PR. Others (Vendtai, et il. Leukemia 9:1121, 1995) have reported similarly encouraging results. We conclude that this regimen can induce CR in pts with both previously mated and untreated AML, even in those with prior MDS with acceptable toxicity. The contribution of each agent and the precise mechanism by which remissions are induced remains to be determined.

Original languageEnglish (US)
Number of pages1
JournalExperimental Hematology
Volume24
Issue number9
StatePublished - Dec 1 1996

Fingerprint

Cytarabine
Granulocyte Colony-Stimulating Factor
Tretinoin
Acute Myeloid Leukemia
Leukemia
Neoplasms
Stiff-Person Syndrome
Musculoskeletal Pain
Lung
Stomatitis
Leukocytosis
Dizziness
Transaminases
Exanthema
Dyspnea
Hypotension
Nausea
Nervous System
Fatigue
Headache

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

@article{89ba4c6c2acc49ea9fa169988fc4a855,
title = "All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia: update of an illinois cancer center phase d pilot study",
abstract = "Thirty-nine pa with non-M3 acute myetoid leukemia (AML) (median age 65) received ATRA ISO mg/mVday (d) onlly, low-oose cylostoe anbinoside (LD Ari-C) 10 mg/m1 twice diily lubcutaneouily d 1-14 lad gnnulocyte cotony-ttimuJatinj factor (G-CSF) (FUgrutim) 5 fif/kf/d nbcuuneouly d 1-28 of ach 2S-d cycle. Pu had either rdipud from prior CR (11 pu), were refractory to prior therapy (11 p), had failed reinduction (3 pu), were previously untreated but had evolved from in antecedent myelodyiplattic syndrome (MDS) (5 pis) or had de amo AML and were older thin 70 yean (9 pts). Pu achieving CR received the identical program but every 6 weeks {or 1 year. Fifteen pts are inevatuaMe for response [11 received < 30 days of treatment due to toxicity (10) or progressive disease (1); 2 died prior to the first follow-up marrow; 2 were ineligible]. Grade m and IV nonbematologic toxichies included headache, hyperfailirubinemia and stomatitis in 4 pts each; pulmonary in 3 (1 dyspnea, 2 pulmonary infiltrates); nausea/email in 3; neurologic in 3 (2 fatigue/weakness, 1 lightheadedness); hypotension in 3; and elevated transaminases, cardiac (trial fibrillation with transient CHF), rash, infection, musculoskeletal pain, the 'stiff man syndrome in 1 pt each. Three pB developed leukocytosis (peak WBC 65.6, 84.0, 123xlOVL). Six (25{\%}) of the 24 {\'e}valuable pts achieved CR, 4 (17{\%}) partial remission (PR), 4 (17) stable disease and 10 (42{\%}) progressive disease. Among the 14 previously untreated pts, 4 (29{\%}) achieved CR, and 1 (7{\%}) PR. Others (Vendtai, et il. Leukemia 9:1121, 1995) have reported similarly encouraging results. We conclude that this regimen can induce CR in pts with both previously mated and untreated AML, even in those with prior MDS with acceptable toxicity. The contribution of each agent and the precise mechanism by which remissions are induced remains to be determined.",
author = "Tallman, {M. S.} and Miller, {H. J.} and C. Anzig and A. Radmaker and Gordon, {Leo I} and D. Hakimian and D. Variakojis and P. Stiff and S. French and {Benson III}, {Al B}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "9",

}

All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia : update of an illinois cancer center phase d pilot study. / Tallman, M. S.; Miller, H. J.; Anzig, C.; Radmaker, A.; Gordon, Leo I; Hakimian, D.; Variakojis, D.; Stiff, P.; French, S.; Benson III, Al B.

In: Experimental Hematology, Vol. 24, No. 9, 01.12.1996.

Research output: Contribution to journalArticle

TY - JOUR

T1 - All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia

T2 - update of an illinois cancer center phase d pilot study

AU - Tallman, M. S.

AU - Miller, H. J.

AU - Anzig, C.

AU - Radmaker, A.

AU - Gordon, Leo I

AU - Hakimian, D.

AU - Variakojis, D.

AU - Stiff, P.

AU - French, S.

AU - Benson III, Al B

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Thirty-nine pa with non-M3 acute myetoid leukemia (AML) (median age 65) received ATRA ISO mg/mVday (d) onlly, low-oose cylostoe anbinoside (LD Ari-C) 10 mg/m1 twice diily lubcutaneouily d 1-14 lad gnnulocyte cotony-ttimuJatinj factor (G-CSF) (FUgrutim) 5 fif/kf/d nbcuuneouly d 1-28 of ach 2S-d cycle. Pu had either rdipud from prior CR (11 pu), were refractory to prior therapy (11 p), had failed reinduction (3 pu), were previously untreated but had evolved from in antecedent myelodyiplattic syndrome (MDS) (5 pis) or had de amo AML and were older thin 70 yean (9 pts). Pu achieving CR received the identical program but every 6 weeks {or 1 year. Fifteen pts are inevatuaMe for response [11 received < 30 days of treatment due to toxicity (10) or progressive disease (1); 2 died prior to the first follow-up marrow; 2 were ineligible]. Grade m and IV nonbematologic toxichies included headache, hyperfailirubinemia and stomatitis in 4 pts each; pulmonary in 3 (1 dyspnea, 2 pulmonary infiltrates); nausea/email in 3; neurologic in 3 (2 fatigue/weakness, 1 lightheadedness); hypotension in 3; and elevated transaminases, cardiac (trial fibrillation with transient CHF), rash, infection, musculoskeletal pain, the 'stiff man syndrome in 1 pt each. Three pB developed leukocytosis (peak WBC 65.6, 84.0, 123xlOVL). Six (25%) of the 24 évaluable pts achieved CR, 4 (17%) partial remission (PR), 4 (17) stable disease and 10 (42%) progressive disease. Among the 14 previously untreated pts, 4 (29%) achieved CR, and 1 (7%) PR. Others (Vendtai, et il. Leukemia 9:1121, 1995) have reported similarly encouraging results. We conclude that this regimen can induce CR in pts with both previously mated and untreated AML, even in those with prior MDS with acceptable toxicity. The contribution of each agent and the precise mechanism by which remissions are induced remains to be determined.

AB - Thirty-nine pa with non-M3 acute myetoid leukemia (AML) (median age 65) received ATRA ISO mg/mVday (d) onlly, low-oose cylostoe anbinoside (LD Ari-C) 10 mg/m1 twice diily lubcutaneouily d 1-14 lad gnnulocyte cotony-ttimuJatinj factor (G-CSF) (FUgrutim) 5 fif/kf/d nbcuuneouly d 1-28 of ach 2S-d cycle. Pu had either rdipud from prior CR (11 pu), were refractory to prior therapy (11 p), had failed reinduction (3 pu), were previously untreated but had evolved from in antecedent myelodyiplattic syndrome (MDS) (5 pis) or had de amo AML and were older thin 70 yean (9 pts). Pu achieving CR received the identical program but every 6 weeks {or 1 year. Fifteen pts are inevatuaMe for response [11 received < 30 days of treatment due to toxicity (10) or progressive disease (1); 2 died prior to the first follow-up marrow; 2 were ineligible]. Grade m and IV nonbematologic toxichies included headache, hyperfailirubinemia and stomatitis in 4 pts each; pulmonary in 3 (1 dyspnea, 2 pulmonary infiltrates); nausea/email in 3; neurologic in 3 (2 fatigue/weakness, 1 lightheadedness); hypotension in 3; and elevated transaminases, cardiac (trial fibrillation with transient CHF), rash, infection, musculoskeletal pain, the 'stiff man syndrome in 1 pt each. Three pB developed leukocytosis (peak WBC 65.6, 84.0, 123xlOVL). Six (25%) of the 24 évaluable pts achieved CR, 4 (17%) partial remission (PR), 4 (17) stable disease and 10 (42%) progressive disease. Among the 14 previously untreated pts, 4 (29%) achieved CR, and 1 (7%) PR. Others (Vendtai, et il. Leukemia 9:1121, 1995) have reported similarly encouraging results. We conclude that this regimen can induce CR in pts with both previously mated and untreated AML, even in those with prior MDS with acceptable toxicity. The contribution of each agent and the precise mechanism by which remissions are induced remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0005058852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0005058852&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -